On July 27th, more than 250 attendees from different countries and medical backgrounds joined the third REACT conference. The unique event, hosted by Sheba Medical Center, was created to provide doctors with insight into the latest advances in oncological care, ultimately aiming to improve cancer patient outcomes. Vered Cohen-Herszaft, the Director of Sheba’s Global Patient […]

Peritoneal cancer is a rare malignancy that develops in the peritoneum, a membrane that lines the walls of the abdominal cavity and rests on the abdominal and pelvic organs. Whether originating from a primary tumor within the peritoneum or a metastatic tumor elsewhere in the body, peritoneal cancer is a terminal disease with a poor […]

Headed by Dr. Michael Peled, researcher and attending physician at Sheba’s Institute for Pulmonary Medicine, and Prof. Arie Admon of the Technion – Israel Institute of Technology, the study involved isolating and analyzing peptides (a short chain of amino acids) found in lung fluid, proving that human lymphocyte (a type of white blood cell) antigen […]

CAR T-cell therapy is an advanced treatment for blood cancers, in which T-cells, also known as T-lymphocytes, which are a type of white blood cell involved in the body’s immune response, are re-engineered to attack malignant cells. This is accomplished by modifying the CAR receptors on T-cell membranes so that they bind to antigens on […]

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to conceive a child and turned to Prof. Meirow, Head of Sheba’s Fertility Preservation Center, for help. When Ayelet was first diagnosed with Hodgkin’s lymphoma in 2008, the malignancy was limited […]

Ameloblastoma is a disorder of the jaw involving abnormal tissue growth. It is a very rare (about 1% of all jaw tumors) and slow-growing tumor that develops in the space behind our molar or back teeth. Ameloblastoma can occur over a broad age range, most commonly affecting patients between the ages of 20 and 40. […]